Related Experiment Video

Updated: May 8, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors

Mridul Roy1, Yu-Hao Luo, Mao Ye

  • 1Molecular Biology Research Center, School of Life Science and State Key Laboratory of Medical Genetics of China, Central South University, Changsha, Hunan 410078, China.

Biomed Research International
|August 13, 2013
PubMed

Insights

Nonsmall cell lung cancer (NSCLC) treatments using growth factor receptor tyrosine kinase inhibitors (RTKIs) show promise but have serious side effects. Further research is needed to optimize RTKIs for safer and more effective NSCLC therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Therapeutics

Background:

  • Lung cancer is the leading cause of cancer-related death globally, with NSCLC accounting for 85% of cases.
  • Conventional NSCLC treatments like surgery, radiation, and chemotherapy have limitations and significant side effects.
  • Cancer cells exhibit growth self-sufficiency, necessitating targeted therapies.

Purpose of the Study:

  • To review the development and efficacy of growth factor receptor (GFR) targeted drugs for NSCLC.
  • To explore combination strategies involving GFR tyrosine kinase inhibitors (RTKIs) with other treatments.
  • To assess the benefits and adverse effects of RTKIs in NSCLC treatment.

Main Methods:

  • Literature review of studies on GFR signaling pathways in NSCLC.
  • Analysis of clinical trial data for single-agent RTKIs and combination therapies.
  • Evaluation of treatment outcomes and adverse events associated with RTKIs.

Main Results:

  • RTKIs offer benefits in treating NSCLC by targeting GFR signaling.
  • Combination strategies, including co-inhibition and combining RTKIs with radiation or chemotherapy, are under investigation to enhance efficacy.
  • While RTKIs show increased potency, they are associated with significant adverse effects, sometimes more severe than chemotherapy.

Conclusions:

  • RTKIs represent a promising therapeutic avenue for NSCLC.
  • Further research is crucial to overcome the adverse effects and fully realize the potential of RTKIs in cancer therapeutics.
  • Optimizing RTKI therapy requires a deeper understanding of cancer biology and drug interactions.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: